Income Statement (USD)

Q1 '24 QoQ
Revenue 8.77B 6.3%
Gross Profit 5.26B 1.5%
Cost of Revenue 3.51B 15.9%
Operating expense 4.59B 18.9%
Net Income 2.24B 2.4%
EBITDA 3.21B 10.9%

Balance Sheet (USD)

Q1 '24 QoQ
Total Assets 63.9B 0.1%
Total Liabilities 51.1B 4%
Total Equity 12.8B 18.9%
Shares Outstanding 901M 0.1%

Cash Flow (USD)

Q1 '24 QoQ
Cash from operations 1.17B 473.8%
Cash from investing -1.18B 59.7%
Cash from financing -311M 108.8%



Financial Highlights for Eli Lilly and Company in Q1 '24

Eli Lilly and Company reported a revenue of 8.77B, which is a -6.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. A decline in revenue can be concerning, as it might indicate reduced sales or challenges in the market. It's important to investigate further to understand the underlying causes.

Gross Profit stood at 5.26B, marking a 1.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.

Cost of Revenue was 3.51B, a -15.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.

Operating Expenses for this period were 4.59B, showing a -18.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.

Net Income for the quarter was 2.24B, showing a 2.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.

The company's EBITDA for the quarter was 3.21B, showing a -10.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.

Eli Lilly and Company faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.